Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary tuberculosis: Feasibility and costs

Journal of Public Health Management and Practice

Volumn 13, Issue 3, 2007, Pages 252-262

  Li, Jiehui ^a   Marks, Suzanne M ^b   Driver, Cynthia R ^a,c   Diaz, Francisco A ^a,d   Castro III, Alejandro F ^a,e   De Regner, Annette Figueroa ^a   Gibson, Aurelia E ^a   Dokubo Okereke, Kinta ^a   Munsiff, Sonal S ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Contacts; Costs; HIV; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEASIBILITY STUDY; FEMALE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NEGRO; PATIENT COUNSELING; PATIENT REFERRAL; PRIORITY JOURNAL; SCREENING; SERODIAGNOSIS; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AIDS SERODIAGNOSIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CONTACT TRACING; COST-BENEFIT ANALYSIS; COUNSELING; DISEASE NOTIFICATION; FEASIBILITY STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PUBLIC HEALTH ADMINISTRATION; RADIOGRAPHY, THORACIC; REFERRAL AND CONSULTATION; SOCIOECONOMIC FACTORS; TUBERCULOSIS, PULMONARY;

EID: 34247208159     PISSN: 10784659     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PHH.0000267683.85411.78     Document Type: Article

References (37)

1. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
2. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345-1349.
3. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The pulmonary complications of HIV Infection Study Group. Ann Intern Med. 1997;126:123-132.
4. Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med. 1998;157:19-22.
5. Cohn DL, El-Sadr WM. Treatment of latent tuberculosis infection. In: Reichman LB, Hershfield E, eds. Tuberculosis: A Comprehensive International Approach. 2nd ed. New York: Marcel Dekker Inc; 2000:471-502.
6. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
7. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2003. Atlanta Ga: US Department of Health and Human Services, CDC; 2004.
8. New York City Department of Health and Mental Hygiene. HIV Epidemiology Program: 1st Quarter Report; 2004.
9. Centers for Disease Control and Prevention. Implementation of named HIV reporting - New York City, 2001. MMWR Morb Mortal Wkly Rep. 2004;52(51):1248-1252.
10. Centers for Disease Control and Prevention. Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/ lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep. 1986;35:448-452.
11. American Thoracic Society and Centers for Disease Control and Prevention. Mycobacterioses and the acquired immunodeficiency syndrome. Joint position paper of the American Thoracic Society and the Centers for Disease Control. Am Rev Respir Dis. 1987;136:492-496.
12. Centers for Disease Control and Prevention. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep. 1989;38:236-250.
13. Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1995;44:1-16.
14. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis. 1992;146:1623-1633.
15. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50:1-57.
16. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329-332.
17. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary complications of HIV Infection Study Group. Ann Intern Med. 1993;119:185-193.
18. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033-2038.
19. Centers for Disease Control and Prevention. Missed opportunities for prevention of tuberculosis among persons with HIV infection-selected locations, United States, 1996-1997. MMWR Morb Mortal Wkly Rep. 2000;49:685-687.
20. Reichler MR, Bur S, Reves R, et al. Results of testing forhuman immunodeficiency virus infection among recent contacts of infectious tuberculosis cases in the United States. Int J Tuberc Lung Dis. 2003;7:S471-S478.
21. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol. 2004;160:301-305.
22. Spiegelman, D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162:199-205.
23. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997;126:123-132.
24. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA. 2000;283(11):1445-1450. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
25. Kellerman SE, Lehman JS, Lansky A, et al. HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr. 2002;31:202-210.
26. Aragon R, Kates J, Hoff T. The AIDS Epidemic at 20 Years: The View From America. Menlo Park, Calif: Kaiser Family Foundation; 2001.
27. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Vol 16. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention;2005:14.
28. Teshale E, Kamimoto L. Harris N, et al. Estimated number of HIV-infected persons eligible for and receiving HIV antiretroviral therapy, 2003-United States [Section 42, #167]. Paper presented at: The 12th Conference on Retroviruses and Opportunistic Diseases; February 25, 2005; Boston, Mass.
29. Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counseling and testing in primary care settings: a first look. AIDS. 2000;14:2159-2169.
30. Walensky RP, Weinstein MC, Kimmel AD, et al. Routine in-patient HIV testing: a clinical and economic evaluation of national guidelines. In: Abstract book of the 2003 National HIV Prevention Conference; July 27-30, 2003; Atlanta, Ga. Abstract T3-E1102.
31. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of costeffectiveness. N Engl J Med. 2005;352:586-595.
32. Walensky RP, Losina E, Malatesta L, et al. Effective HIV case identification through routine HIV screening at urgent care centers in Massachusetts. Am J Public Health. 2005;95:71-73.
33. Latkin CA, Knowlton AR. Micro-social structural approaches to HIV prevention: a social ecological perspective. AIDS Care. 2005;(suppl 1):S102-S113.
34. Amirkhanian YA, Kelly JA, McAuliffe TL. Identifying, recruiting, and assessing social networks at high risk for HIV/AIDS: methodology, practice, and a case study in St Petersburg, Russia. AIDS Care. 2005;17(1):58-75.
35. Branson BM, Burstein G. Retarding HIV prevention: initial results from OraQuick postmarketing surveillance. Paper presented at: Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention; August 2003; Atlanta, Ga.
36. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA. 2004;292:219-223.
37. U.S. Food and Drug Administration. Tests waived by FDA from January 2000 to present. 2005. Available at: http:// www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfClia/testswaived. cfm